6 results match your criteria: "Associate Professor in the Department of Medicine at McMaster University in Hamilton[Affiliation]"
Approach to the detection and management of chronic kidney disease: What primary care providers need to know.
Can Fam Physician
October 2018
Associate Professor in the Department of Medicine at McMaster University in Hamilton, Ont, a staff nephrologist and Nephrology Division Director at St Joseph's Healthcare Hamilton, and Provincial Medical Lead (Chronic Kidney Disease Care) at the Ontario Renal Network.
Objective: To help primary care providers, both family physicians and nurse practitioners, identify, detect, and manage patients with and at risk of chronic kidney disease (CKD), as well as outline criteria for appropriate referral to nephrology.
Sources Of Information: Published guidelines on the topic of CKD and its comorbidities were reviewed. A MEDLINE search was conducted using the MeSH terms and .
Management of bone health in patients with celiac disease: Practical guide for clinicians.
Can Fam Physician
June 2018
Professor of Pediatrics and Medicine in the Division of Gastroenterology and Nutrition in the Department of Pediatrics at Dalhousie University in Halifax, NS, Member of the Professional Advisory Council for the Canadian Celiac Association.
Article Synopsis
- Bone health is at risk for patients with celiac disease (CD) due to inflammation and malabsorption of calcium and vitamin D, affecting both adults and children.
- Most adults are found to have low bone mass at the time of CD diagnosis, necessitating monitoring through bone mineral density tests and annual vitamin D level checks.
- Along with a strict gluten-free diet, these patients should receive calcium and vitamin D supplementation and engage in weight-bearing exercises to maintain bone health and prevent osteoporosis.
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.
Can Fam Physician
May 2018
Assistant Professor in the Department of Family Medicine at the University of Ottawa, Adjunct Assistant Professor in the School of Pharmacy at the University of Waterloo in Ontario, and Scientist at the Bruyère Research Institute.
Objective: To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper and stop benzodiazepine receptor agonists (BZRAs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes.
Methods: The overall team comprised 8 clinicians (1 family physician, 2 psychiatrists, 1 clinical psychologist, 1 clinical pharmacologist, 2 clinical pharmacists, and 1 geriatrician) and a methodologist; members disclosed conflicts of interest. For guideline development, a systematic process was used, including the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.
Objective: To address common "what if" questions that arise relating to the long-term clinical follow-up and management of patients receiving the new oral anticoagulants (NOACs).
Sources Of Information: For this narrative review, we searched the PubMed database for recent (January 2008 to week 32 of 2013) clinical studies relating to NOAC use for stroke prevention in atrial fibrillation and for the treatment of acute venous thromboembolism. We used this evidence base to address prespecified questions relating to NOAC use in primary care settings.
Objective: To compare key features of the new oral anticoagulants (NOACs)-dabigatran, rivaroxaban, and apixaban-and to address questions that arise when comparing the NOACs.
Sources Of Information: PubMed was searched for recent (January 2008 to week 32 of 2013) clinical studies relating to NOAC use for stroke prevention in atrial fibrillation (AF) and for the treatment of acute venous thromboembolism (VTE).
Main Message: All NOACs are at least as effective as warfarin for stroke prevention in patients with nonvalvular AF, and are at least as safe in terms of bleeding risk according to 3 large trials.